Questions? Feedback? powered by Olark live chat software roche Archives - eMedics.org

Welcome to eMEDICS.org! your IT partner for Patient Management

Opening Hours : Monday to Friday - 9am to 5pm
  Contact : +33.6.95.06.31.17

All Posts Tagged: roche

google harvard symptom patient monitoring

Monitoring Device Market Worth US$ 1,502.9 Mn by 2024

Global remote patient monitoring device market is expected to expand at a CAGR of 6.7% and is estimated to reach US$ 1,502.9 Mn by 2024, creating incremental opportunity of US$ 657.1 Mn between 2016 and 2024. Persistence Market Research analyzes the overall performance of the global remote patient monitoring device market and provides key insights on the factors and trends likely to influence the market during this eight-year period.

Rising prevalence of cardio vascular diseases, respiratory disorders, and diabetes in the general population are major factors driving the growth of the global remote patient monitoring device market. Increasing healthcare expenditure and increasing availability of effective treatment solutions for chronic diseases is also projected to boost revenue growth of the global remote patient monitoring device market. Other factors boosting market growth include an increasing awareness among people to self-monitor before disease advancement and government reimbursement issued on homecare settings facilities.

Lack of trained professionals to help with remote patient monitoring devices is expected to hinder market growth of the global remote patient monitoring device market. Insufficiency in maintaining the privacy and security of the stored data, lack of uniformity in device functionality, and lack of general awareness on patient monitoring devices are the key restraints challenging the market.

Global remote patient monitoring device market is segmented on the basis of Product Type (Cardiac Monitors, Respiratory Monitors, Hematological Monitors), Application (Cardiac Arrhythmia, Diabetes, Ischemic diseases, Hypertension, Sleep apnea, Chronic respiratory diseases, Hyperlipidemia), End User (Hospitals, Homecare Settings, Long-term Care Centers, Others), and Region (North America, Latin America, Europe, APEJ, and MEA).

By product type, the cardiac monitors segment is expected to remain the largest segment and is anticipated to reach US$ 765.4 Mn by the end of 2024, expanding at a CAGR of 6.9% over the forecast period. By the end of 2024, the respiratory monitors segment is projected to reach US$ 435.0 Mn, expanding at a CAGR of 6.5% over the forecast period. By application, the cardiac arrhythmia segment is estimated to reach US$ 307.7 Mn by 2024, expanding at a CAGR of 6.8% over the forecast period. The diabetes segment is projected to reach US$ 196.8 Mn by 2024, expanding at a CAGR of 5.6% over the forecast period. By end user, the hospitals segment is anticipated to reach US$ 690.1 Mn by 2024, expanding at a CAGR of 6.6% over the forecast period. The homecare settings segment is anticipated to reach US$ 347.3 Mn by 2024, expanding at a CAGR of 6.2% over the forecast period.

Among regions, North America is estimated to dominate the global remote patient monitoring device market with 31.4% revenue share of the overall market by the end of 2016. The Europe remote patient monitoring device market is anticipated to reach US$ 341.1 Mn by 2024. By 2024, North America and Europe markets are expected to account for over four-fifth share of the global remote patient monitoring device market revenue.

Some key companies covered in the report include Boston Scientific Corporation, Koninklijke Philips N.V., Abbott Laboratories, Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., LifeWatch AG, Medtronic, and St. Jude Medical. These companies are primarily focused on enhancing their product portfolio through research and development initiatives and through the introduction of innovative technologies in order to gain higher market share and to strengthen their respective positions in the global market.

Read More

Roche app measures Parkinson’s disease fluctuations

This is another fine example of how smartphones could be used to good effect in modern day medicine. Roche Pharma Research & Early Development (pRED) has developed a smartphone-based monitoring system for those with Parkinson’s disease (PD) that complements the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations. This could be the first time that such an app has been used to measure disease and symptom severity in a medicine development program in Parkinson’s disease.

“The app is being used in a Phase I trial run by Prothena, in collaboration with Roche in PD. In clinical trials in this area, disease disability and impairment are traditionally measured by physician assessments using the Unified Parkinson’s Disease Rating Scale (UPDRS). However, these are limited to the specific times that patients go for an appointment with their physicians. The app will enable continuous measurement of PD fluctuation every day and throughout the day. Ultimately, we hope the app can be used in future clinical development to enable  more objective measures on response to treatment to complement doctor assessments,” explains Anirvan Ghosh, Head of Neuroscience Discovery for pRED.

Patients will be asked to follow a daily routine with the app, using it every day for the duration of the trial. The routine will consist of six active tests followed by passive monitoring. These assessments are designed to provide information on a person’s symptoms, their progress and impact on daily life. The app has been developed in consultation with Max Little, a pioneer in PD app development who is best known for his work on the Parkinson’s Voice Initiative. Max is Assistant Professor at Aston University and is associated with Oxford University and the MIT Media Lab. The project has also been presented to the Michael J. Fox Foundation for Parkinson’s Research.

A series of Roche activities

“The data collected will be used to predict patient UPDRS scores and study symptom fluctuations throughout the duration of the trial. In addition, patient adherence data will be used to assess the patient’s willingness to adopt technology which will be beneficial for future trials,” says Christian Czech, Group Leader in Neuroscience Biomarker Experimental Medicine, pRED.

The active tests will ask patients to do a series of 30-second long activities. These include:

  • Voice test: conducting an “aaah” sound for as long as possible
  • Balance test: standing still
  • Gait test: walking 20 yards, including an 180 degree turn
  • Dexterity test: tapping two buttons alternately on the touchscreen with the dominant use hand
  • Rest tremor test: holding the smartphone in the hand most affected by the tremor, resting it on the lap and counting back from 100
  • Postural tremor test: holding the smartphone in the same hand, outstretched

For passive monitoring, patients are asked to carry the smartphone with them throughout the day. Data is then collected from the various smartphone sensors. Patients will be asked to use the app for the duration of the trial, including screening, dosing and follow-up, which may last up to a period of about 32 weeks.

Key role of investigators

The app is equipped with dashboards that show the patient’s compliance level. Based on this information, investigators can guide patients to use the app more regularly. Additionally, we can also monitor how much data is coming in from the smartphones. Based on this, we can ask investigators to speak with patients who should be using the app more regularly,” points out Christian Gossens, Head of Early Development Workflows, pRED Informatics.

The app has been developed for Android and it has been deployed to the trial on a Samsung Galaxy S3 Mini. Roche provides patients with dedicated, preconfigured smartphones for the sole purpose of remote patient monitoring via the app. This makes the device and the app easier to use for the elderly patient population.

Speaking about the project, Max Little said, “It was clear that Roche had the vision to recognise the value and potential of this technology, and the resources to make this a reality. It has been an exciting experience to see the concept take shape over the last couple of years.”

Read More
December 16, 2015 / Posted by / Roche app measures Parkinson’s disease fluctuations